BRAUN
From its home of IPL at its world-class innovation facility in Kronberg, Germany, the pioneering German electronics brand, Braun, today introduces the Braun Skin i·expert - the only fully connected IPL system that learns, adapts, and provides personalised feedback in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131964639/en/
Braun Skin i·expert. Fully connected IPL system. (Photo: Business Wire)
The revolutionary new Skin i·expert is Braun’s fastest way to 1 year of smooth skin*, all in the comfort of your own home.
A smart system that automatically adapts the energy to your skin tone providing you with an active real-time personalised treatment guidance per body area – Braun puts the power in your hands, offering a more comfortable hair removal experience with the new Braun Skin i·expert.
All IPL devices within the Braun portfolio have been designed to offer fast, safe, almost painless hair removal and undergo countless R&D tests and scientific research to deliver the desired results you want and need.
Braun IPL devices are assessed by independent dermatologists and certified by Skin Health Alliance's high skin safety standards
- Smart Coverage Feedback and Smart Head Recognition enables you to achieve your best results by guiding you in real-time to avoid missing any treatment areas.
- The only one** with automatic flash power adaptation to your unique skin tones and a Skin Check to achieve your best results, in full safety. Followed by personalized tips on how you can improve your next session.
- No need to worry about missing an appointment thanks to its built in Personal Progress Tracker and Smart Calendar that enables you to stay on track by automatically adapting the sessions schedule by showing you how many treatments you still have left. Take control of your hair removal journey with ease and at a fraction of the cost of going to a salon.
Braun’s new IPL smart device is a step change to your hair removal routine, it gives the power to you to get long-lasting smooth skin safely, easily from the comfort of your home.
Ahmed Aboulenein, Global Vice President at Braun, said: “At Braun's Kronberg Innovation Center, our team are committed to designing durable and user-centered innovations that leverage cutting-edge technologies. Our aim is to delight consumers and address their Grooming everyday problems effectively. By gathering insights and data from consumers worldwide, Braun has identified a need for solutions that enable users to achieve safe and long-lasting smooth skin at home. This valuable information has informed our latest breakthrough IPL innovation. Our ultimate objective is to empower consumers, allowing them to achieve safe, long-lasting smooth skin comfortably from the convenience of their own homes. What sets the new Braun Skin i-expert apart is its seamless integration of smart technology, connecting the IPL device with a dedicated mobile app. This comprehensive system learns and adapts to the user's specific skin and hair needs, guiding them step by step through the entire treatment process. It provides real-time personalized feedback, making it remarkably user-friendly for both experienced IPL users and beginners.”
Dr. Christine Dierickx, MD, a leading cosmetic dermatologist and Director of Skinperium Laser and Cosmetic Dermatology Clinic in Luxembourg, said: “Hair removal is one of the top three reasons why patients visit a dermatologist. Many consumers opt also for salons as they believe at-home devices are complicated and do not deliver the desired results. The Braun Skin i·expert is a unique device that has been developed after years of research. It features an intuitive smart system that makes hair removal extremely simple for consumers. The device learns use after use to provide a personalized experience tailored just to you. Additionally, the automatic flash power adapts to your unique skin tones to ensure you achieve the best results, in full safety. The new Braun Skin i·expert is set to revolutionize the way we remove hair at home.”
*Following the regimen. Individual results may vary.
**Shared technology with Cyden
***Further reading: Hattersley AM, Kiernan M, Goldberg D, Dierickx C, Sliney DH, Haedersdal M, et al. Assessment of adverse events for a home‐use intense pulsed light hair removal device using postmarketing surveillance. Lasers Surg Med. 2023;1–9. https://doi.org/10.1002/lsm.23650
Notes to editors
About Braun
Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality and distinctive design. These range from electric shavers and beauty products to household appliances, watches and speakers. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131964639/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom